BIOMAT Database Logo BIOMAT Database Logo

Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. 1996

R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Department of Biochemistry and Molecular Biology, University of Alcalá, Alcalá de Henares, Spain.

Vasoactive intestinal peptide (VIP) is an important member of the group of neuropeptides that appears to be involved in the regulation of prostatic growth and function. Here we studied VIP receptors in membranes from human benign hyperplastic prostate. Accordingly to observations in rat prostatic membranes, [125I]VIP binding to human prostatic membranes suggested two classes of binding sites with high Kd = 0.22 nM) and low (Kd = 37.7 nM) affinities. VIP bound in human and rat membrane preparations to a common VIP/pituitary adenylate cyclase-activating peptide (PACAP) receptor, as VIP, PACAP-27, and PACAP-38 were equipotent for competition of [125I]VIP binding. A PACAP-preferring receptor appears to be expressed in human prostate, since [125I]PACAP binding was displaced with more potency by PACAP than by VIP, and a messenger RNA corresponding to type I PACAP receptor was found. Cross-linking experiments suggested a VIP receptor of about 71 kDa in human and 52 kDa in rat prostates. The binding of [125I]VIP to membranes and the labeling of the bands observed after electrophoresis were competitively inhibited by GTP, suggesting the coupling of VIP receptors to a G protein. Moreover, after solubilization and cross-linking, we observed a 120-kDa band that corresponded to the VIP receptor-alpha s association. VIP stimulated adenylyl cyclase activity in a dose-dependent manner, but the potency and/or the efficacy of VIP were lower in all human preparations studied than in rat prostatic membranes. In conclusion, this study clearly demonstrates the expression of VIP/PACAP common receptors associated with alpha s protein in human prostate and suggests that these neuropeptides could play an important and complex role in the physiology and pathophysiology of this human gland.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009479 Neuropeptides Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells. Neuropeptide
D011467 Prostate A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. Prostates
D011468 Prostatectomy Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE). Prostatectomy, Retropubic,Prostatectomy, Suprapubic,Prostatectomies,Prostatectomies, Retropubic,Prostatectomies, Suprapubic,Retropubic Prostatectomies,Retropubic Prostatectomy,Suprapubic Prostatectomies,Suprapubic Prostatectomy
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011979 Receptors, Pituitary Hormone Cell surface proteins that bind pituitary hormones with high affinity and trigger intracellular changes influencing the behavior of cells. Since many pituitary hormones are also released by neurons as neurotransmitters, these receptors are also found in the nervous system. Pituitary Hormone Receptors,Receptors, Pituitary Hormones,Pituitary Hormones Receptors
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes

Related Publications

R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
April 2003, Journal of molecular neuroscience : MN,
R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Receptors for pituitary adenylate cyclase-activating polypeptide: comparison with vasoactive intestinal peptide receptors.
October 1992, Trends in endocrinology and metabolism: TEM,
R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
February 2016, Current opinion in endocrinology, diabetes, and obesity,
R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Identification and characterization of five-transmembrane isoforms of human vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors.
December 2006, Genomics,
R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
June 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors.
October 2005, The Journal of pharmacology and experimental therapeutics,
R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
January 2004, Polish journal of pharmacology,
R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Vascular effects of pituitary adenylate cyclase activating peptide: a comparison with vasoactive intestinal peptide.
August 1992, Regulatory peptides,
R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Receptors for pituitary adenylate cyclase-activating peptide in human liver.
August 1995, The Journal of clinical endocrinology and metabolism,
R M Solano, and M J Carmena, and I Carrero, and S Cavallaro, and F Roman, and C Hueso, and S Travali, and N Lopez-Fraile, and L G Guijarro, and J C Prieto
Pituitary adenylate cyclase activating peptide: a novel vasoactive intestinal peptide-like neuropeptide in the gut.
January 1992, Neuroscience,
Copied contents to your clipboard!